Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00575380 · ClinicalTrials.gov registry record · Phase 4
Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery
A Phase 4 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 4
- Development phase
- 116
- Enrollment target
NCT00575380 is a Phase 4 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 116 participants.
The verdict
NCT00575380, a Phase 4 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 116 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the drug concentrations in the conjunctiva and aqueous humor of AzaSite™ compared to Vigamox® in subjects undergoing routine cataract surgery
Interventions
- DRUG AzaSite Eye Drops
- DRUG Vigamox Eye Drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2007-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00575380
The ClinicalTrials.gov registry entry for NCT00575380 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AzaSite Eye Drops is the first listed.
NCT00575380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00575380 about?
NCT00575380 is a clinical study titled "Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery". The purpose of this study is to evaluate the drug concentrations in the conjunctiva and aqueous humor of AzaSite™ compared to Vigamox® in subjects undergoing routine cataract surgery
What is the current status of trial NCT00575380?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 116 participants. The study started on 2007-12.
What interventions are being tested in trial NCT00575380?
The interventions under investigation include: AzaSite Eye Drops (DRUG), Vigamox Eye Drops (DRUG).
Who is sponsoring clinical trial NCT00575380?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.